Author(s): Mittal Rakesh | Ramaswamy N | Pandita R | Al Bahar S | Khalifa N | Omar S
Journal: Indian Journal of Medical and Paediatric Oncology
ISSN 0971-5851
Volume: 31;
Issue: 1;
Start page: 33;
Date: 2010;
Original page
Keywords: Acute myeloid leukemia | chemotherapy | osteosarcoma | secondary malignancy
ABSTRACT
Secondary acute myeloid leukemia (sAML) is a rare complication following chemotherapy for osteogenic sarcoma. However, the exact offending drug is difficult to prove as there is no consistent data. It usually develops 2 years after completion of therapy. We report a case of sAML that developed within 8 months of completing the treatment. The patient was treated with cisplatin, doxorubicin and high-dose methotreaxate followed by surgery (amputation). Eight months after completion of therapy, while on follow-up, he presented with leukocytosis and thrombocytopenia and confirmed to have AML.
Journal: Indian Journal of Medical and Paediatric Oncology
ISSN 0971-5851
Volume: 31;
Issue: 1;
Start page: 33;
Date: 2010;
Original page
Keywords: Acute myeloid leukemia | chemotherapy | osteosarcoma | secondary malignancy
ABSTRACT
Secondary acute myeloid leukemia (sAML) is a rare complication following chemotherapy for osteogenic sarcoma. However, the exact offending drug is difficult to prove as there is no consistent data. It usually develops 2 years after completion of therapy. We report a case of sAML that developed within 8 months of completing the treatment. The patient was treated with cisplatin, doxorubicin and high-dose methotreaxate followed by surgery (amputation). Eight months after completion of therapy, while on follow-up, he presented with leukocytosis and thrombocytopenia and confirmed to have AML.
